Table 3 Hodgkin's lymphoma treatment response analysis.
Clinical data | N | Complete response (%) | N | Refractory/ relapsed (%) | p value |
|---|---|---|---|---|---|
Gender | |||||
Male | 13 | 72.2 | 5 | 27.8 | 0.286 |
Female | 17 | 85.0 | 3 | 15.0 | |
HL Subtype | |||||
Nodular sclerosis | 21 | 84.0 | 4 | 16.0 | 0.220 |
Mixed cellularity | 5 | 55.6 | 4 | 44.4 | |
Lymphocyte predominant | 2 | 100.0 | 0 | 0 | |
Unclassified | 2 | 100.0 | 0 | 0 | |
Ann Arbor staging | |||||
Early (I or II) | 15 | 88.2 | 2 | 11.8 | 0.195 |
Advanced (III or IV) | 15 | 71.4 | 6 | 28.6 | |
EBV status | |||||
Negative | 21 | 100.0 | 0 | 0 | < 0.001 |
Positive | 9 | 52.9 | 8 | 47.1 | |
CTA positivity | |||||
0 CT | 24 | 80.0 | 6 | 20.0 | 0.954 |
> or = 1 | 6 | 75.0 | 2 | 25.0 | |
MAGE-A | |||||
negative | 24 | 77.4 | 7 | 22.6 | 0.538 |
positive | 6 | 85.7 | 1 | 14.3 | |
CT7 | |||||
negative | 27 | 81.8 | 6 | 18.2 | 0.279 |
positive | 3 | 60 | 2 | 40 |